Drugs / ET019002- T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03642496 | Aug 2018 → Aug 2020 | B-cell neoplasm | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET019002- T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03642496 ↗ |
| Modality | Cell therapy | “ET019002-T cell therapy is a novel chimeric T-cell therapy platform” NCT03642496 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT03642496 ↗ |
| Target | CD19 | “ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor” NCT03642496 ↗ |